Apyx Medical Corp

For the period ended Mar 31, 2024. Filed May 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

APYX$2.94+0.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets at

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

	March 31, 2024(Unaudited)	December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$37,282	$43,652
Trade accounts receivable, net of allowance of $605 and $608	12,487	14,023
Inventories, net of provision for obsolescence of $880 and $875	9,795	9,923
Prepaid expenses and other current assets	2,362	2,764
Total current assets	61,926	70,362
Property and equipment, net of accumulated depreciation and amortization of $3,642 and $3,522	1,779	1,915
Operating lease right-of-use assets	5,049	5,162
Finance lease right-of-use assets	64	69
Other assets	1,893	1,732
Total assets	$70,711	$79,240
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$2,103	$2,712
Accrued expenses and other current liabilities	8,077	9,661
Current portion of operating lease liabilities	356	347
Current portion of finance lease liabilities	20	20
Total current liabilities	10,556	12,740
Long-term debt, net of debt discounts and issuance costs	33,406	33,185
Long-term operating lease liabilities	4,795	4,896
Long-term finance lease liabilities	48	53
Long-term contract liabilities	1,252	1,246
Other liabilities	194	198
Total liabilities	50,251	52,318
EQUITY
Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of March 31, 2024 and December 31, 2023	—	—
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,926 issued and outstanding as of March 31, 2024 and 34,643,888 issued and outstanding as of December 31, 2023	35	35
Additional paid-in capital	82,242	81,114
Accumulated deficit	(62,024)	(54,448)
Total stockholders' equity	20,253	26,701
Non-controlling interest	207	221
Total equity	20,460	26,922
Total liabilities and equity	$70,711	$79,240

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.